A Study of Econazole Foam 1% in Athlete’s Foot

Overview

This is a 6-week clinical study (4 weeks of treatment, once per day, plus a 2-week follow-up period) of a topical foam to treat athlete's foot. The active ingredient in the foam – econazole nitrate 1% — is the same active pharmaceutical ingredient in a cream that your doctor can currently prescribe to treat athlete's foot. This study will help to understand if the foam works the same as the cream to treat athlete's foot.

Full Title of Study: “A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 2008

Detailed Description

Treating athlete's foot with a cream can leave a greasy, wet feeling on the foot that is uncomfortable to the user and messy on clothing and foot wear. A foam formulation that spreads easily and rubs-in easily that is as effective as the (reference) cream formulation in treating athlete's foot would be a benefit to the user. This study is designed to substantiate a clinical bridge between econazole nitrate foam 1% and econazole nitrate cream 1% based on clinical outcome, safety, and pharmacokinetic data. The study is (foam) vehicle-controlled and is randomized 1 to 1 to 1 (foam:cream:vehicle).

Interventions

  • Drug: Econazole Nitrate Cream 1%
    • Topical cream, applied once daily for 4 weeks.
  • Drug: Econazole Nitrate Foam 1%
    • Topical foam, applied once daily for 4 weeks.
  • Drug: Vehicle Foam
    • Topical foam, applied once daily for 4 weeks.

Arms, Groups and Cohorts

  • Active Comparator: 1
    • Econazole Nitrate Cream 1%
  • Experimental: 2
    • Econazole Nitrate Foam 1%
  • Placebo Comparator: 3
    • Vehicle Foam

Clinical Trial Outcome Measures

Primary Measures

  • Complete Cure Rate: Interdigital Disease
    • Time Frame: Day 43
    • A negative KOH and negative culture and no evidence of clinical disease as indicated by scores of 0 for each sign and symptom at Day 43.
  • Complete Cure Rate: Moccasin Disease
    • Time Frame: 43 Days
    • A negative KOH and negative culture and no evidence of clinical disease as indicated by scores of 0 for each sign and symptom at Day 43.

Secondary Measures

  • Effective Treatment: Interdigital Disease
    • Time Frame: 43
    • Negative KOH, negative fungal culture, no or mild (a score of 0 or 1) erythema and/or scaling with all other signs or symptoms being absent (score = 0) at Day 43 (Week6).
  • Effective Treatment: Mocassin Disease
    • Time Frame: 43
    • Negative KOH, negative fungal culture, no or mild (a score of 0 or 1) erythema and/or scaling with all other signs or symptoms being absent (score = 0) at Day 43 (Week6).
  • Mycological Cure: Interdigital Disease
    • Time Frame: 43
    • Negative KOH and negative fungal culture at Day 43
  • Mycological Cure: Mocassin Disease
    • Time Frame: 43
    • Negative KOH and negative fungal culture at Day 43

Participating in This Clinical Trial

Inclusion Criteria

  • Be at least 18 years or age and of either sex. – Has a clinical diagnosis of tinea pedis with at least i) moderate scaling(interdigital and/or moccasin) and ii) mild erythema (interdigital only). – Be willing to give informed consent. – Be willing and able to give informed consent. – Has microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte at Baseline. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture. – Be in good health and free of any disease or physical condition which might, in the investigator's opinion, expose the subject to an unacceptable risk by study participation. – Women of childbearing potential must have a negative urine pregnancy test and agree to use an effective, non-prohibited form of birth control for the duration of the study (abstinence, stabilized on oral contraceptives for at least two months, implant, injection, IUD, patch, NuvaRing, condom and spermicidal or diaphragm and spermicidal). Exclusion Criteria:

  • Is nursing or planning a pregnancy during the study. – Has used topical antifungal or corticosteroid therapy or systemic antibacterial therapy within 30 days prior to the start of the study. – Has received systemic antifungal therapy within 12 weeks prior to the start of the study medication. – Has a history of diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications). – Has concurrent tinea infection (in the opinion of the investigator). However, concurrent onychomycosis is allowed. – Has any other skin disease which might interfere with the evaluation of tinea pedis. – Is currently enrolled in an investigational drug or device study. – Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study – Is unreliable, including subjects with a history of drug or alcohol abuse. – Has known hypersensitivity to any of the components of the study medications.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AmDerma
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.